The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters

Article Immunology

Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

Yaki Saciuk et al.

Summary: A retrospective cohort study in Israel showed that a third dose of the BNT162b2 vaccine provides added protection against SARS-CoV-2 infection, especially for those vaccinated six months ago. The vaccine's effectiveness was found to be 92.9% in terms of prevention of infection, highlighting the importance of booster doses in maintaining immunity.

JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

Barbara A. Cohn et al.

Summary: This study reports the effectiveness of vaccines against SARS-CoV-2 infection and death in veterans, with a decline in vaccine effectiveness observed for all vaccine types. The decline was greatest for the Janssen vaccine. However, vaccination remained protective against death for individuals who became infected during the Delta variant surge. The study also found variations in the vaccine effectiveness against death among different age groups.

SCIENCE (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination

Michael Klompas

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Noa Eliakim-Raz et al.

Summary: This study focuses on evaluating the anti-S IgG antibody levels before and after the administration of a third dose of the BNT162b2 vaccine in individuals aged 60 and older in Israel.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021

Sarah Mbaeyi et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Microbiology

Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response

Sally A. Mahmoud et al.

Summary: This study evaluated the performance of six commercially available serological assays for detecting SARS-CoV-2 antibodies, with Roche Elecsys showing the highest sensitivity, Genscript cPass having the highest specificity, and Diasorin-TrimericS IgG demonstrating the best overall performance. Lowering the cutoff of Genscript cPass significantly improved sensitivity and agreement with the gold standard PRNT results.

MICROBIOLOGY SPECTRUM (2021)

添加到收藏夹

News Item Multidisciplinary Sciences

COVID VACCINE BOOSTERS: THE MOST IMPORTANT QUESTIONS

Ewen Callaway

Summary: Some countries are considering deploying extra vaccine doses in response to concerns over waning immunity and SARS-CoV-2 variants, but it is still unclear to scientists whether most people need them.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

S. J. Thomas et al.

Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

News Item Multidisciplinary Sciences

THE RACE FOR CORONAVIRUS VACCINES

Ewen Callaway

NATURE (2020)

添加到收藏夹

The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters

相关参考文献

导出引文

分享论文